Integrated Filing — IndAS



General information about company

Scrip Code 540222
NSE Symbol LAURUSLABS
MSEI Symbol NOTLISTED
ISIN INE947Q01028
Name of company LAURUS LABS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 23-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 09-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Manufacturer of Generics API, Generics FDF, Synthesis and Bio Technology
Start date and time of board meeting 23-10-2025   14:00:00
End date and time of board meeting 23-10-2025   14:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,65,347.00 3,22,304.00
Other income 2,696.00 3,739.00
Total income 1,68,043.00 3,26,043.00
2 Expenses
(a) Cost of materials consumed 67,675.00 1,27,616.00
(b) Purchases of stock-in-trade 3,070.00 6,920.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (4,401.00) (4,457.00)
(d) Employee benefit expense 21,556.00 43,036.00
(e) Finance costs 4,000.00 9,150.00
(f) Depreciation, depletion and amortisation expense 12,049.00 23,733.00
(f) Other Expenses
1 Other Expenses 37,121.00 70,650.00
Total other expenses 37,121.00 70,650.00
Total expenses 1,41,070.00 2,76,648.00
3 Total profit before exceptional items and tax 26,973.00 49,395.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 26,973.00 49,395.00
6 Tax expense
7 Current tax 8,791.00 14,793.00
8 Deferred tax (1,193.00) (881.00)
9 Total tax expenses 7,598.00 13,912.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 19,375.00 35,483.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 74.00 134.00
16 Total profit (loss) for period 19,449.00 35,617.00
17 Other comprehensive income net of taxes (567.00) (638.00)
18 Total Comprehensive Income for the period 18,882.00 34,979.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 19,497.00 35,799.00
Total profit or loss, attributable to non-controlling interests (48.00) (182.00)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 18,930.00 35,161.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests (48.00) (182.00)
21 Details of equity share capital
Paid-up equity share capital 10,796.00 10,796.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.61 6.63
Diluted earnings (loss) per share from continuing operations 3.61 6.63
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.61 6.63
Diluted earnings (loss) per share from continuing and discontinued operations 3.61 6.63
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1 The above consolidated unaudited financial results of Laurus Labs Limited (the Company) including its subsidiaries (Collectively known as the Group), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 23, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2025. 2 These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India 3 The consolidated financials include the results of the following entities Please see table in the results pdf 4 a The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited in India on December 01, 2022. LSCPL has not commenced its operations. b During the quarter ended June 30, 2025, the company has invested Rs 40 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F Prime Capital Investors c Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited KRKA, Capital contribution have been made into KRKA interms of the aforesaid agreement during the quarter ended December 31, 2024 for 49 percent stake. The Company has accounted for the investment in KRKA as joint venture w.e.f. October 03, 2024. 5 Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited, capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30, 2025 . The Company has accounted for its investment in Kurnool Renewables as an associate w.e.f May 12, 2025. 6 The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments 7 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi under section 230 and 232 of the Companies Act, 2013 and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company for the quarter and six months ended September 30, 2025, quarter ended June 30, 2025, quarter and six months ended September 30, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger. 8 During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of Rs 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. 9 The Board of Directors, at their meeting held on October 23, 2025 approved for the payment of interim dividend of Rs 0.80 per equity share of Rs 2 each



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 3,80,023.00
Capital work-in-progress 54,081.00
Investment property 0.00
Goodwill 24,630.00
Other intangible assets 1,773.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 26,132.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 4,642.00
Total non-current financial assets 30,774.00
Deferred tax assets (net) 725.00
Other non-current assets 30,369.00
Total non-current assets 5,22,375.00
2 Current assets
Inventories 2,02,096.00
Current financial asset
Current investments 0.00
Trade receivables, current 1,85,944.00
Cash and cash equivalents 4,977.00
Bank balance other than cash and cash equivalents 1,361.00
Loans, current 153.00
Other current financial assets 634.00
Total current financial assets 1,93,069.00
Current tax assets (net) 0.00
Other current assets 23,985.00
Total current assets 4,19,150.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 9,41,525.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,796.00
Other equity 4,69,743.00
Total equity attributable to owners of parent 4,80,539.00
Non controlling interest 12,814.00
Total equity 4,93,353.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 53,877.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 5,426.00
Total non-current financial liabilities 59,303.00
Provisions, non-current 11,282.00
Deferred tax liabilities (net) 2,502.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 57,567.00
Total non-current liabilities 1,30,654.00
Current liabilities
Current financial liabilities
Borrowings, current 1,61,058.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 4,038.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 97,398.00
Total Trade payable 1,01,436.00
Other current financial liabilities 28,942.00
Total current financial liabilities 2,91,436.00
Other current liabilities 12,075.00
Provisions, current 3,097.00
Current tax liabilities (Net) 10,910.00
Deferred government grants, Current 0.00
Total current liabilities 3,17,518.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 4,48,172.00
Total equity and liabilites 9,41,525.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 (i) Remeasurement gains/(losses) on defined benefit plans (26.00) (51.00)
2 ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods 7.00 13.00
3 iii) Share in other comprehensive income of the associates and joint ventures, nert of tax (1.00) (1.00)
Total Amount of items that will not be reclassified to profit and loss (20.00) (39.00)
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating the financial statements of foreign operations (547.00) (599.00)
Total Amount of items that will be reclassified to profit and loss (547.00) (599.00)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (567.00) (638.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 49,395.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (8,602.00)
Adjustments for decrease (increase) in trade receivables, current 12,474.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (2,205.00)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 5,914.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 23,733.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 25,381.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (1,926.00)
Adjustments for dividend income 0.00
Adjustments for interest income 483.00
Adjustments for share-based payments 541.00
Adjustments for fair value losses (gains) 441.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 55,268.00
Net cash flows from (used in) operations 1,04,663.00
Dividends received 0.00
Interest paid (8,866.00)
Interest received 0.00
Income taxes paid (refund) 9,425.00
Other inflows (outflows) of cash 5,209.00
Net cash flows from (used in) operating activities 1,09,313.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 907.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 297.00
Purchase of property, plant and equipment 48,891.00
Proceeds from sales of investment property 0.00
Purchase of investment property 1,765.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 483.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 3,106.00
Net cash flows from (used in) investing activities (47,677.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1,895.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 4,376.00
Repayments of borrowings 59,044.00
Payments of lease liabilities 641.00
Dividends paid 4,314.00
Interest paid 9,068.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (66,796.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (5,160.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 183.00
Net increase (decrease) in cash and cash equivalents (4,977.00)
Cash and cash equivalents cash flow statement at beginning of period 9,954.00
Cash and cash equivalents cash flow statement at end of period 4,977.00